Better safe than sorry: dual targeting antibodies for cancer immunotherapy
Author:
Schoenfeld Katrin1, Harwardt Julia1, Kolmar Harald12ORCID
Affiliation:
1. Institute for Organic Chemistry and Biochemistry , Technical University of Darmstadt , Peter-Grünberg-Strasse 4, D-64287 Darmstadt , Germany 2. Centre for Synthetic Biology , Technical University of Darmstadt , Darmstadt , Germany
Abstract
Abstract
Antibody-based therapies are revolutionizing cancer treatment and experience a steady increase from preclinical and clinical pipelines to market share. While the clinical success of monoclonal antibodies is frequently limited by low response rates, treatment resistance and various other factors, multispecific antibodies open up new prospects by addressing tumor complexity as well as immune response actuation potently improving safety and efficacy. Novel antibody approaches involve simultaneous binding of two antigens on one cell implying increased specificity and reduced tumor escape for dual tumor-associated antigen targeting and enhanced and durable cytotoxic effects for dual immune cell-related antigen targeting. This article reviews antibody and cell-based therapeutics for oncology with intrinsic dual targeting of either tumor cells or immune cells. As revealed in various preclinical studies and clinical trials, dual targeting molecules are promising candidates constituting the next generation of antibody drugs for fighting cancer.
Publisher
Walter de Gruyter GmbH
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry
Reference165 articles.
1. Alley, S.C., Okeley, N.M., and Senter, P.D. (2010). Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14: 529–537, https://doi.org/10.1016/j.cbpa.2010.06.170. 2. Alvarez-Argote, J. and Dasanu, C.A. (2019). Durvalumab in cancer medicine: a comprehensive review. Expert. Opin. Biol. Ther. 19: 927–935, https://doi.org/10.1080/14712598.2019.1635115. 3. Bachanova, V., Frankel, A.E., Cao, Q., Lewis, D., Grzywacz, B., Verneris, M.R., Ustun, C., Lazaryan, A., McClune, B., Warlick, E.D., et al.. (2015). Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin. Cancer Res. 21: 1267–1272, https://doi.org/10.1158/1078-0432.ccr-14-2877. 4. Baruah, H., Chang, G., Cheung, A., Grinberg, A., Juo, Z., and Mcquade, T. (2020). Proteins binding NKG2D, CD16 and FLT3. US201962915123P A61K39/395;A61P35/00;C07K16/28;C07K16/30;C07K16/46. 5. Baulida, J., Kraus, M.H., Alimandi, M., Di Fiore, P.P., and Carpenter, G. (1996). All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271: 5251–5257, https://doi.org/10.1074/jbc.271.9.5251.
|
|